Trulicity - Global Strategic Business Report

The global market for Trulicity was valued at US$4.9 Billion in 2025 and is projected to reach US$6.4 Billion by 2032, growing at a CAGR of 3.9% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Trulicity (Dulaglutide) Market - Key Trends & Drivers Summarized

What Clinical Role Does Trulicity Play?

Trulicity (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to improve glycemic control in type 2 diabetes. By amplifying insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, it enables robust A1C reduction while promoting weight loss. Its long-acting formulation and autoinjector delivery increase adherence and predictability compared to daily GLP-1 therapies.

What Innovations Are Expanding Trulicity’s Reach?

Latest dose presentations include higher-quantitative units for improved A1C control. Its single-dose autoinjector features hidden needle and simplified device feedback that ease patient use. Cardiovascular outcome trial data (REWIND) show significant reduction in major adverse cardiovascular events (MACE) in diabetic adults - pushing prescribing into cardio-metabolic risk management. Real-world integration into value-based care and telehealth further streamlines therapy initiation and adherence monitoring.

Who Is Trulicity Serving?

Primary-care physicians, diabetes educators, and endocrinologists frequently prescribe it to newly diagnosed T2DM patients needing dual glycemic and weight benefits. Clinical cardiologists are increasingly prescribing Trulicity for diabetic patients with ASCVD risks. Within pharmacist-led chronic care clinics, it's used for protocolized titration. Telemedicine programs serving rural or medically underserved communities adopt it due to ease of training and remote follow-up.

What’s Driving the Adoption of Trulicity?

The growth in the Trulicity market is driven by increasing type 2 diabetes prevalence, strong cardio-renal outcome data, preference for weekly dosing convenience, and broader reimbursement from payers prioritizing GLP-1s with CV benefit. Its real-world effectiveness in reducing A1C and body weight together strengthens market position. Novel prescription copay programs and manufacturer support services improve access. As guidelines increasingly recommend GLP-1s early in treatment, Trulicity remains a preferred option in both specialist and primary-care environments.

Report Scope

The report analyzes the Trulicity market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Indication (Type 2 Diabetes Indication, Obesity Indication, Cardiovascular Disease Indication); Form (Injection Form, Pen Device Form, Pre-Filled Syringe Form); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel); End-Use (Hospitals End-Use, Homecare Settings End-Use, Other End-Uses)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Type 2 Diabetes Indication segment, which is expected to reach US$3.3 Billion by 2032 with a CAGR of a 3.0%. The Obesity Indication segment is also set to grow at 5.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2025, and China, forecasted to grow at an impressive 6.5% CAGR to reach $1.3 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Trulicity Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Trulicity Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Trulicity Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Trulicity market report include:

• Amgen
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• GlaxoSmithKline
• Innovent Biologics
• Jiangsu Hansoh Pharma Group
• Merck & Co.
• Novartis
• Novo Nordisk
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Roche / Genentech
• Sanofi
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
• Valo Therapeutics
• Zealand Pharma

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.